Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Isotretinoin
Drug ID BADD_D01213
Description Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued.[L6574] Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States.[L6579] The first isotretinoin-containing product was FDA approved on 7 May 1982.[L6574]
Indications and Usage Isotretinoin is indicated to treat severe recalcitrant nodular acne and patients ≥12 years enrolled in the iPLEDGE program.[Label,L6579]
Marketing Status approved
ATC Code D10AD04; D10BA01
DrugBank ID DB00982
KEGG ID D00348
MeSH ID D015474
PubChem ID 5282379
TTD Drug ID D00DKK
NDC Product Code 10631-133; 65655-0006; 0245-0573; 61748-303; 61748-304; 72143-252; 0832-8304; 65655-0003; 65977-0135; 55111-136; 61748-302; 69238-1176; 0591-2435; 72143-232; 10631-116; 10631-118; 57664-023; 68308-573; 0555-1056; 72143-253; 57664-020; 10631-003; 10631-005; 64566-0003; 0378-6614; 68308-570; 69238-1175; 0591-2434; 0591-2501; 72143-233; 0832-8302; 10631-007; 10631-117; 57664-025; 0378-6611; 68308-571; 69238-1017; 72143-251; 72143-254; 64566-0004; 65655-0005; 0245-0570; 61748-301; 68308-575; 0555-1057; 0591-2433; 0591-2436; 10631-002; 10631-115; 10631-134; 64566-0014; 65655-0004; 76055-0010; 0245-0575; 0378-6612; 0555-1055; 72143-231; 0832-8303; 17337-0024; 55111-113; 69238-1174; 0591-2451; 72143-234; 0832-8301; 55111-137; 57664-022; 0555-1054; 67262-0003; 71052-426; 0245-0571; 55111-135; 57664-021; 57664-024
UNII EH28UP18IF
Synonyms Isotretinoin | 13-cis-Retinoic Acid | 13 cis Retinoic Acid | Isotretinoin Zinc Salt, 13-cis-Isomer | Isotretinoin Zinc Salt, 13 cis Isomer | Roaccutane | Accutane | Ro 4-3780 | Ro 4 3780 | Ro 43780
Chemical Information
Molecular Formula C20H28O2
CAS Registry Number 4759-48-2
SMILES CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diverticulum07.10.01.0010.002959%Not Available
Diverticulum intestinal07.10.01.0020.000386%Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug interaction08.06.03.001--Not Available
Dry eye06.08.02.0010.058714%
Dry mouth07.06.01.0020.011861%
Dry skin23.03.03.0010.240209%
Dry throat22.12.03.005; 07.06.01.0050.002573%Not Available
Duodenitis07.08.03.0010.000257%Not Available
Dwarfism05.03.02.002; 15.02.03.0050.000386%Not Available
Dyshidrotic eczema23.03.04.0340.000643%Not Available
Dysmenorrhoea21.01.01.0020.002264%
Dysphagia07.01.06.003--
Dysphonia22.12.03.006; 19.19.03.002; 17.02.08.004--
Ear disorder04.03.01.001--Not Available
Ear pain04.03.01.0030.001647%
Ectopic pregnancy18.02.02.0020.003345%Not Available
Eczema23.03.04.0060.017676%
Eczema nummular23.03.04.0350.000386%Not Available
Emotional disorder19.04.02.0050.012221%Not Available
Endometriosis21.07.01.0040.001518%Not Available
Endophthalmitis06.04.05.009; 11.01.06.003--
Enteritis07.08.03.0020.002702%
Epiphyses premature fusion05.05.03.002; 15.02.02.0010.005017%Not Available
Episcleritis10.02.01.024; 06.04.07.0010.000643%Not Available
Epistaxis24.07.01.005; 22.04.03.0010.105156%
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Erythema nodosum23.07.02.001; 10.02.01.0200.003139%Not Available
Euphoric mood19.04.02.006--
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene